Valuation: NovoCure Limited

Market Cap 1.88B 1.63B 1.54B 1.39B 2.62B 180B 2.64B 18.38B 7.07B 91.47B 7.06B 6.91B 292B P/E 2026 *
-12.9x
P/E 2027 * -19.8x
Enterprise Value 1.78B 1.54B 1.45B 1.32B 2.47B 170B 2.49B 17.35B 6.68B 86.34B 6.67B 6.52B 275B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.08x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day+3.90%
1 week-5.77%
Current month-6.08%
1 month-4.33%
3 months-2.28%
6 months+37.40%
Current year+28.88%
1 week 12.97
Extreme 12.97
14.2
1 month 12.97
Extreme 12.97
15.18
Current year 8.12
Extreme 8.118
17.24
1 year 8.12
Extreme 8.118
17.24
3 years 8.12
Extreme 8.118
32.57
5 years 8.12
Extreme 8.118
144.6
10 years 5.18
Extreme 5.179
203.2
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Change 5-day change 1-year change 3-year change Capi.($)
+3.90%-5.77% - - 1.89B
-0.45%-1.16%+16.76%+18.17% 12.6B
+0.04%-2.26%+12.42%+16.89% 6.64B
+0.18%-5.48% - - 6.18B
+0.06%-4.94%+20.93%+9.00% 5.58B
-1.23%+0.98%-18.28%+42.04% 5.15B
+2.24%+2.04%-33.26%-23.26% 3.78B
-0.43%-9.98%+32.92%-17.69% 1.89B
0.00%+6.83%-4.39%+164.64% 1.77B
+1.60%-2.25%+48.32%-16.80% 1.59B
Average +0.59%-1.81%+9.43%+24.12% 5.02B
Weighted average by Cap. +0.15%-1.79%+8.24%+19.26%

Financials

2026 *2027 *
Net sales 726M 629M 595M 538M 1.01B 69.63B 1.02B 7.09B 2.73B 35.3B 2.73B 2.67B 113B 805M 697M 659M 597M 1.12B 77.2B 1.13B 7.87B 3.03B 39.14B 3.02B 2.96B 125B
Net income -142M -123M -116M -105M -198M -13.62B -199M -1.39B -534M -6.91B -534M -522M -22.03B -84.78M -73.44M -69.44M -62.87M -118M -8.13B -119M -829M -319M -4.12B -318M -311M -13.15B
Net Debt -105M -91.37M -86.4M -78.22M -147M -10.12B -148M -1.03B -397M -5.13B -396M -387M -16.36B -210M -182M -172M -156M -292M -20.14B -294M -2.05B -789M -10.21B -789M -771M -32.56B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change
15/09/26 €14.13 +3.90%
14/09/26 €13.60 +4.82%
11/09/26 €12.97 -1.56%
10/09/26 €13.18 -5.59%
09/09/26 €13.96 -6.72%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.15USD
Average target price
27.14USD
Spread / Average Target
+68.07%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!